Royalty Report: Drugs, Pharmaceuticals, Therapeutic – Collection: 796

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Therapeutic
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 796

License Grant
The Purchaser entered into an Asset Purchase Agreement with the Company, to acquire all rights, title and interest to iferanserin ointment, or VEN 309, for the topical treatment of symptomatic hemorrhoids.
Field of Use
The rights granted apply to the medical industry.

IPSCIO Record ID: 3164

License Grant
On November 14, 2011, the Licensee completed its acquisition from the Licensor, of all rights, title and interest to iferanserin ointment, or VEN 309.
License Property
Closing was subject to, in respect of the first pivotal Phase III trial and any recurrence treatment for VEN 309, the absence through November 10, 2011 of any serious severe adverse events that were life threatening with a risk of serious morbidity that occurred in one or more subjects receiving VEN 309 which are either determined to be at least probably caused by VEN 309 or have been disclosed by us in a public securities filing.

Iferanserin (VEN 309) is for the topical treatment of hemorrhoids, for which the first Phase III clinical trial began in August 2011 and is ongoing.

Field of Use
The Field of Use apply to the medical industry.

IPSCIO Record ID: 3384

License Grant
We have acquired the worldwide exclusive rights to manufacture and sell from a Company in Basingstoke, England, Ice Baton®.
License Property
Ice Baton provides an innovative, natural ice treatment for hemorrhoids that avoids the possible complications and patient limitations associated with existing chemical topical ointment treatments. Ice Baton has been FDA approved and has received a CE mark for sale in Europe.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.